Venture Life Group Plc · LSE:VLG
Venture Life — FY2025 Earnings Presentation
27 slides from Venture Life's earnings presentation, April 2026
Slide 1: Results update for the 12 months ended 31st December 2025
Results update for the 12 months ended 31st December 2025 April1 2026
Slide 2: Key Highlights
Key Highlights Key Highlights The Group has simplified its business model, becoming a pure play consumer healthcare company with a capital light, brand-focused, omnichannel approach. Strategic reinvestment, new leadership appointments, and strong cash resources support acquisition-ready infrastructu
Slide 3: Financial Headlines
Financial Headlines Financial Headlines • Group revenue increased 32.2% to £35.2 million (2024: £26.6 million) and 11.4% on a proforma basis. • Gross profit increased 30.0% to £15.8 million (2024: £12.2 million) at gross margin of 45.0% (2024: 45.8%) (2024 proforma: 45.2%). • Marketing costs as a pe
Slide 4: Revenue increased 11.4% on a proforma basis in FY2025 & the Power Brands grew 14.9%
REVENUE INCREASED 11.4% ON A PROFORMA BASIS IN FY2025 & THE POWER BRANDS GREW 14.9% CATEGORY BRANDS FY2025 REVENUE % OF GROUP REVENUE IN FY2025 OVERALL GROWTH % UK GROWTH % Women’s Intimate Health £8.8m 25.0% +16.8% +12.5% Hormone Health* £8.5m 24.1% +44.1% +44.1% Energy Management £10.0m 28.4% +6.4
Slide 5: Strong revenue and gross profit progression – Adjusted EBITDA margin decline
Strong revenue and gross profit progression – Adjusted EBITDA margin decline in FY25 reflects the temporary disproportionate position of the operating cost base following the divestments - the deployment of the Group’s significant cash resources into M&A activities is expected to drive immediately e
Slide 6: Revenues from the Power Brands have grown consistently
REVENUES* FROM THE POWER BRANDS HAVE GROWN CONSISTENTLY 10,000 6,200 8,000 Balance Activ Earol Lift 9,000 6,000 7,000 8,000 5,800 6,000 7,000 5,600 Women’s 6,000 Health 5,000 5,400 5,000 4,000 5,200 4,000 3,000 5,000 3,000 4,800 2,000 2,000 1,000 4,600 1,000 FY24 REVENUE - 4,400 - FY22A FY23A FY24A
Slide 7: Corporate Development
Corporate Development Corporate Development • Restructured the commercial and marketing functions, including consolidation of international business management into the UK • New ERP system went live in December 2025 • July 2025 - Divestment of CDMO operations and some small brands, launch of new foc
Slide 8: M&A Strategy
MA Strategy M&A Strategy • Complementary categories, adjacencies • Margin enhancing • Sensibly priced • Asset purchases preferred • Currently interacting with targets • Watch this space 8
Slide 9: Technology & Digital
Technology Digital Technology & Digital CURRENT ACTIVITY STRATEGY OUTCOME • Completed the first stage of • Building a Digital and Data • Insight focused digitally our ERP Implementation in strategy. driven business. 2025 • Establishing data • Understanding trends and • Building a data lake house own
Slide 10: Brands progress
Brands progress 10
Slide 11: Hormonal Health
Hor mona l Healt h 12 11
Slide 12: Hormonal Health 2025, (Revenue +44%)
Hormonal Health 2025, (Revenue +44%) Hormonal Health 2025, (Revenue +44%) Health & Her and Health & Him +44% +27% Active Products New Products 2025 Distribution Net Revenue Points • Retail: Range extensions for new multivitamin range secured in Boots, H&B and CVS. Health & Him brand rolled out into
Slide 13: Hormonal Health 2026 Plans
Hormonal Health 2026 Plans Hormonal Health 2026 Pla ns Health & Her and Health & Him Active Produc ts New Produc ts 2026 +5,192 +9 distribution pts New Products • Retail: Rollout of maternal range into Boots • Longevity innovation: New range of Longevity Supplements will extend the brand into this e
Slide 14: Women’s Intimate Health
® BALANCE ACTIV" BV Treatment Gel cng grey reat a Be eee coat am
Slide 15: Women’s Intimate Health 2025, (Revenue +13.3%)
Women’s Intimate Health 2025, (Revenue +13.3%) +12.5% +20.9% UK Revenue growth International Partner YoY Brand Revenue Growth • Recently launched treatment conditions demonstrating good organic growth due to key product extensions in retail and consumer awareness • Thrush cream growing at 19.8% as c
Slide 16: Women’s Intimate Health 2026
Women’s Intimate Health 2026 +3,350 Distribution Pts YoY +20% Weighted dist YoY • Innovation: 2 significant new launches into Dual Action and Test Kits have very well received by retailers – launching in Q2-Q3 • First ever TV and bathroom media campaigns targeting BV awareness opportunity and New We
Slide 17: Discover the UK’s No1 Perimenopause Brand
Discover the UK’s N o1* Perimenopause Brand *IRI, Women’s Health category, value sales, 12 wks to 4th Sept 2021, Total Market August 2025
Slide 18: Energy Management 2025 (Revenue +6.4%)
Energy Management 2025 (Revenue +6.4%) Energy Management 2025 (Revenue +6.4%) +41% Website growth +29% Lift Growth in Ireland • Online channel is up +26% with Amazon and lift.com performing well with 41% growth vs. 2024 • Glucogel launch on Amazon UK is also delivering incremental sales and benefiti
Slide 19: Energy Management 2026 Plans
Energy Management 2026 Plans Energy Management 2026 Plans +2,352 Distribution Point Growth • Launching a new range of innovation under the Lift brand including gels, paper-wrapped packs and kids offering • Delivering a far-reaching education campaign to HCPs to highlight the superiority vs. dietary
Slide 20: Slide 20
Slide 21: ENT 2025 (Revenue -2.1%)
ENT 2025 (Revenue -2.1%) ENT 2025 (Revenue -2.1%) “UK’s No.1 ear wax removal spray” +11.5% UK rev growth YoY +1,400 new distribution points • Earol Distribution Expansion in Sainsburys, Morrisons and WH Smith saw an increase of +1400 distribution points • Launch into 553 Holland & Barrett stores has
Slide 22: ENT 2026 Plan
ENT 2026 Plan ENT 2026 Plan +995 Dist Points Growth +1 New Retailer 2026 • Launching two proposition extensions in the range – Earol SWIM & Shower (previously SWIM) and Earol Junior (previously Baby) • New radio campaign will drive awareness around the signs of wax – i.e. hearing loss and promote Ea
Slide 23: International Business Update
International Business Update 23
Slide 24: Transforming our International Distributor GTM Model
Transforming our International Distributor GTM Model Shifting from a sell-in approach to one focused on accelerating International Partnered Brand expansion through license & supply of VLG formulation/IP via Strategic Partnerships. This transition moves us away from transactional contracting and tow
Slide 25: Strategic Partnerships for Mutually Profitable Growth
Strategic Partnerships for Mutually Profitable Growth Whilst overall international revenues declined 1.9% to £10.1 million (2024 proforma: £10.3 million), the Power Brands grew by 8.0% internationally to £8.1 million (2024: £7.5 million) – driven by growth from our most strategic partners: Cooper -
Slide 26: Post Period & Outlook
Post Period Outlook Post Period & Outlook Post Period End • Revenues trading c.18% ahead of prior year with healthy gross margin improvement. • H&H officially became the No.1 menopause supplement brand in the UK (Circana Value Sales Data). • Monitoring Middle East developments – orders extended out
Slide 27: Thank You
Thank You The ambition: The Partner of choice for Proactive Healthy Longevity